ERBB2 and neoplasm: A side by side comparison of HER2bsFab with trastuzumab has been conducted in vitro and in a mouse model to characterize its anti-tumor efficacy against high- and low-HER2-overexpressing, as well as trastuzumab-refractive breast cancer tumors.